SCYNEXIS, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SCYNEXIS, Inc. - overview
Location
-, NC, US
Primary Industry
Pharmaceuticals
About
SCYNEXIS, Inc. is a biopharmaceutical company focused on developing innovative antifungal therapies for serious infections. Their pioneering approach addresses the urgent need for effective treatments against antifungal-resistant pathogens. SCYNEXIS, Inc.
develops antifungal treatments specifically targeting serious fungal infections. Headquartered in Durham, North Carolina, the company has pivoted its focus over the years, emphasizing the commercialization of its lead drug, Ibrexafungerp. SCYNEXIS, Inc. was founded by a team of experienced professionals in the pharmaceutical industry.
The company has engaged in multiple funding rounds, most notably raising USD 45. 00 mn in a Private Placement on April 2022, contributing to a total amount raised of USD 45. 00 mn. The company's CEO is Marco Taglietti.
SCYNEXIS specializes in the development and commercialization of antifungal therapies, focusing on difficult-to-treat fungal infections. Their lead product, Ibrexafungerp, represents a novel class known as 'fungerps' and is designed to combat antifungal-resistant pathogens. The company's products target healthcare providers, particularly hospitals and specialty clinics, where the incidence of these infections is rising. SCYNEXIS markets its products across North America and Europe, addressing the pressing need for effective antifungal treatments.
In 2023, SCYNEXIS reported revenue of USD 140. 14 mn, alongside an EBITDA of USD -37. 12 mn. The company's revenue model is primarily based on direct sales to healthcare institutions and partnerships with pharmaceutical distributors, driven by the sales of Ibrexafungerp through tailored pricing structures for institutional buyers.
SCYNEXIS, Inc. plans to utilize its recent funding to further develop and launch new antifungal products aimed at expanding its market reach. The company is targeting additional markets in Europe and Asia for its treatments, with strategic timelines for expansion yet to be disclosed. The funds raised through the latest Private Placement will support ongoing clinical trials and product development efforts, reinforcing the company's commitment to combating antifungal resistance in healthcare settings.
Current Investors
Alta Partners, Burrill & Company, Ventech
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.scynexis.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
SCYNEXIS, Inc. - timeline of key events
SCYNEXIS, Inc. - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 19,024,000 | 257,000 | 257,000 | 257,000 | 257,000 | 121,000 | - | 13,163,000 | 5,091,000 | - | - | - |
| % Revenue Growth (YoY) | - | (98.6%) | - | - | - | (52.9%) | (100.0%) | - | (61.3%) | - | - | - |
| EBITDA (USD) | (10,119,000) | (27,902,000) | (27,376,000) | (25,755,000) | (29,613,000) | (47,639,000) | (49,837,000) | (59,156,000) | (83,562,000) | - | - | - |
| Operating Income (USD) | (12,112,000) | (28,349,000) | (27,817,000) | (26,320,000) | (29,983,000) | (48,921,000) | (51,149,000) | (60,838,000) | (85,757,000) | - | - | - |
| Operating Margin | (63.7%) | (11030.7%) | (10823.7%) | (10241.2%) | (11666.5%) | (40430.6%) | - | (462.2%) | (1684.5%) | - | - | - |
| % EBITDA Margin | (53.2%) | (10856.8%) | (10652.1%) | (10021.4%) | (11522.6%) | (39371.1%) | - | (449.4%) | (1641.4%) | - | - | - |
| NET Income (USD) | (4,234,000) | (32,623,000) | (29,989,000) | (25,060,000) | (12,468,000) | (53,710,000) | (55,185,000) | (32,866,000) | (62,809,000) | - | - | - |
| % Net Margin | (22.3%) | (12693.8%) | (11668.9%) | (9751.0%) | (4851.4%) | (44388.4%) | - | (249.7%) | (1233.7%) | - | - | - |
SCYNEXIS, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.